Triplet-targeted therapy improves survival for patients with advanced colorectal cancer and BRAF mutations
Abstract: LBA32
The three-drug combination of encorafenib, binimetinib and cetuximab significantly improved overall survival (OS) in patients with BRAF-mutated metastatic colorectal cancer (mCRC), according to results of the BEACON CRC Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
The treatment combination resulted in median OS of 9 months for the combination therapy compared...
Targeted therapy erdafitinib effective for patients with advanced bladder cancer and specific gene mutations
Treatment with the FGFR inhibitor erdafitinib in patients with metastatic bladder cancers marked by mutations in the FGFR3 gene resulted in...
MD Anderson honored to rank as nation’s best hospital for cancer care in annual survey
The University of Texas MD Anderson Cancer Center is honored to be ranked No. 1 in cancer care in the U.S. News & World Report’s annual...
Discovery shows how difficult-to-treat prostate cancer evades immune system
Researchers at The University of Texas MD Anderson Cancer Center have discovered how an aggressive form of prostate cancer called double-negative prostate cancer (DNPC) metastasizes by evading the immune system. The investigators also reported on the pre-clinical development of a new therapy, which, when given in combination with existing immunotherapies, appears to stop and even reverse metastasis in mouse models.
DNPC is difficult...
New biomarker-guided strategy has potential for liver cancer treatment
A study at The University of Texas MD Anderson Cancer Center discovered a cellular pathway tied to cancer that may be beneficial in reducing...
Fewer than half of U.S. adults exposed to court-ordered anti-smoking advertisements
The tobacco industry’s court-ordered anti-smoking advertisements reached just 40.6% of U.S. adults and 50.5% of current smokers in 2018, according...
Joel Dahmen named MD Anderson's official PGA TOUR ambassador
The University of Texas MD Anderson Cancer Center, the official cancer center of the PGA TOUR, today announced its partnership with Joel Dahmen...